Question 1

What specific type of B-ALL do I have, and how does it relate to this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Orphan Indications for CD19 Redirected Autologous T Cells clinical trial (NCT04276870). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of CART19 treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Orphan Indications for CD19 Redirected Autologous T Cells clinical trial (NCT04276870). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options I might have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Orphan Indications for CD19 Redirected Autologous T Cells clinical trial (NCT04276870). Contact the study team or your healthcare provider for specific answers.

Question 4

What is the process for receiving CART19, and how long will it take?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Orphan Indications for CD19 Redirected Autologous T Cells clinical trial (NCT04276870). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks I should be aware of, especially regarding my current health status?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Orphan Indications for CD19 Redirected Autologous T Cells clinical trial (NCT04276870). Contact the study team or your healthcare provider for specific answers.

Question 6

What follow-up care will I need after treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Orphan Indications for CD19 Redirected Autologous T Cells clinical trial (NCT04276870). Contact the study team or your healthcare provider for specific answers.

What this study is about